(Q39289876)

10 September 2017

title

Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 months (English)

1 reference

10 September 2017

1 reference

1 reference

I K Jang

1

1 reference

10 September 2017

J Vanhaecke

2

1 reference

10 September 2017

H De Geest

3

1 reference

10 September 2017

M Verstraete

4

1 reference

10 September 2017

D Collen

5

1 reference

10 September 2017

F Van de Werf

6

1 reference

10 September 2017

language of work or name

English

0 references

publication date

1 December 1986

1 reference

Journal of the American College of Cardiology

10 September 2017

published in

1 reference

10 September 2017

volume

8

1 reference

10 September 2017

issue

6

1 reference

10 September 2017

page(s)

1455-1460

1 reference

Human tissue-type plasminogen activator: from the laboratory to the bedside

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980323-0

7 January 2021

Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980323-0

7 January 2021

Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980323-0

7 January 2021

The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980323-0

7 January 2021

Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980323-0

7 January 2021

Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980323-0

7 January 2021

Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980323-0

7 January 2021

Variability in the measurement of regional left ventricular wall motion from contrast angiograms.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980323-0

7 January 2021

Coronary thrombolysis for evolving myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980323-0

7 January 2021

Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980323-0

7 January 2021

Effect of interventions in salvaging left ventricular function in acute myocardial infarction: a study of intracoronary streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980323-0

7 January 2021

Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980323-0

7 January 2021

Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2886%2980323-0

7 January 2021

10.1016/S0735-1097(86)80323-0

Identifiers

DOI

1 reference

10 September 2017

1 reference